Please provide your email address to receive an email when new articles are posted on . CV benefits of PCSK9 inhibition with evolocumab may be stronger in patients with autoimmune or inflammatory ...

Please provide your email address to receive an email when new articles are posted on . Evolocumab is the first PCSK9 inhibitor to demonstrate effectiveness in primary and secondary prevention ...

Coverage of a new PCSK9 trial makes bold claims about prevention and risk reduction. But how well do they hold up to scrutiny ...

Most stand-alone Medicare Part D prescription drug plans and Medicare Advantage plans that include drug coverage cover Repatha, an injectable medication for high cholesterol and cardiovascular disease ...

One group received evolocumab injections under the skin every two weeks while the other group received injections of a placebo every two weeks. The data showed that, after an average of 4.6 years, ...

BETHESDA, MD — The US Food and Drug Administration (FDA) has approved the evolocumab (Repatha, Amgen) Pushtronex system, the first once-monthly delivery option for a proprotein convertase subtilisin ...

In the United States, evolocumab injection already has been approved by the FDA. The medication is indicated to reduce the risk of heart attack and stroke in adults with established cardiovascular ...